Repeated Cytoreduction Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Selected Patients Affected by Peritoneal Metastases: Italian PSM Oncoteam Evidence.
cytoreductive surgery
hyperthermic intraperitoneal chemotherapy
peritoneal metastases
peritoneal-surface malignancy
repeated CRS-plus-HIPEC
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
18 Jan 2023
18 Jan 2023
Historique:
received:
07
11
2022
revised:
23
12
2022
accepted:
16
01
2023
entrez:
11
2
2023
pubmed:
12
2
2023
medline:
12
2
2023
Statut:
epublish
Résumé
The reiteration of surgical cytoreduction (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients affected by recurrent peritoneal metastases is still questioned regarding safety and effectiveness. This study evaluates the safety, efficacy, and associated factors of iterative CRS combined with HIPEC. This multicentric retrospective study collected data from four surgical oncology centers, on iterative HIPEC. We gathered data on patient and cancer characteristics, the peritoneal cancer index (PCI), completeness of cytoreduction (CC), postoperative complications, and overall survival (OS). In the study period, 141 CRS-plus-HIPECs were performed on 65 patients. Nine patients underwent three iterative procedures, and one underwent five. No increased incidence of complications after the second or third procedure was observed. Furthermore, operative time and hospitalization stay were significantly shorter after the second than after the first procedure (
Identifiants
pubmed: 36765565
pii: cancers15030607
doi: 10.3390/cancers15030607
pmc: PMC9913411
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Cancer Research UK
ID : 29365
Pays : United Kingdom
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Ann Surg Oncol. 2009 Oct;16(10):2744-51
pubmed: 19626375
Cancer. 2010 Dec 15;116(24):5608-18
pubmed: 20737573
J Clin Oncol. 2006 Aug 20;24(24):4011-9
pubmed: 16921055
Langenbecks Arch Surg. 2011 Oct;396(7):1077-81
pubmed: 21842290
Ann Surg. 1995 Jan;221(1):29-42
pubmed: 7826158
In Vivo. 2022 May-Jun;36(3):1527-1533
pubmed: 35478133
Ann Surg. 2001 Aug;234(2):198-205
pubmed: 11505065
Ann Surg Oncol. 2020 May;27(5):1448-1455
pubmed: 31873928
Int J Hyperthermia. 2017 Aug;33(5):562-570
pubmed: 28124576
J Clin Oncol. 2010 Jan 1;28(1):63-8
pubmed: 19917863
Int J Hyperthermia. 2014 Dec;30(8):565-9
pubmed: 25430988
J Am Coll Surg. 2012 Sep;215(3):412-7
pubmed: 22634117
Pleura Peritoneum. 2022 Mar 15;7(2):51-61
pubmed: 35812007
Clin Colon Rectal Surg. 2005 Aug;18(3):204-14
pubmed: 20011303
Ann Surg Oncol. 2004 Apr;11(4):375-9
pubmed: 15070596
Anticancer Res. 2018 Sep;38(9):5521-5524
pubmed: 30194211
Cancer. 2000 Jan 15;88(2):358-63
pubmed: 10640968
Eur J Gynaecol Oncol. 2016;37(5):638-643
pubmed: 29787001
J Clin Oncol. 2012 Jul 10;30(20):2449-56
pubmed: 22614976
JAMA. 1961 Oct 21;178:261-6
pubmed: 13887881
Ann Surg Oncol. 2022 Jun;29(6):3390-3401
pubmed: 35133518
J Clin Oncol. 2009 Dec 20;27(36):6237-42
pubmed: 19917862
Ann Surg Oncol. 2019 May;26(5):1445-1453
pubmed: 30825033
Ann Oncol. 2007 May;18(5):827-34
pubmed: 17130182
Lancet Oncol. 2006 Jan;7(1):69-76
pubmed: 16389186
Eur J Surg Oncol. 2003 Feb;29(1):69-73
pubmed: 12559080
Minerva Chir. 2014 Feb;69(1):27-35
pubmed: 24675244
J Surg Oncol. 2012 Aug 1;106(2):197-203
pubmed: 22331814
J Surg Oncol. 2019 Sep;120(4):794-802
pubmed: 31309588
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Anticancer Res. 2014 May;34(5):2363-8
pubmed: 24778044
Eur J Surg Oncol. 2010 Mar;36(3):309-14
pubmed: 19615849
Cancer Treat Res. 1996;82:359-74
pubmed: 8849962
Cancer. 2008 Jul 15;113(2):315-25
pubmed: 18473354
J Surg Oncol. 2008 Sep 15;98(4):295-9
pubmed: 18726900
Ann Surg Oncol. 2007 Aug;14(8):2289-99
pubmed: 17541772
Ann Surg. 2007 Apr;245(4):597-603
pubmed: 17414609
J Surg Oncol. 2011 Nov 1;104(6):692-8
pubmed: 21713780